STOCK TITAN

Processa Pharmaceuticals Inc - PCSA STOCK NEWS

Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.

Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.

Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.

The company's current pipeline includes three promising NGC treatments:

  • NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
  • PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
  • PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.

Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas. The conference is on November 16 – 17, 2023, at the Revere Hotel Boston Common. Dr. Young will be available for one-on-one meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
conferences
-
Rhea-AI Summary
Processa Pharmaceuticals announces the formation of its Oncology Advisory Board to assist in the design of oncology trial protocols, including the anticipated Phase 2 trial for NGC-Cap. The board comprises key opinion leaders from renowned institutions. Processa aims to develop next-generation chemotherapeutic drugs to enhance cancer treatment efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
management
-
Rhea-AI Summary
Processa Pharmaceuticals to present updated corporate overview at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.45%
Tags
conferences
Rhea-AI Summary
Processa Pharmaceuticals to present corporate overview at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
conferences
-
Rhea-AI Summary
Processa Pharmaceuticals provides interim analysis of Phase 1B trial for NGC-Cap chemotherapy treatment. Personalized dosing regimen shows potential to improve safety and efficacy. Currently, capecitabine is dosed universally, leading to reduced efficacy and side effects. Early results are encouraging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
management
-
Rhea-AI Summary
Processa Pharmaceuticals CEO, Dr. David Young, to present at MedInvest Oncology Investor Conference on June 21-22, 2023 in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
Rhea-AI Summary
Processa Pharmaceuticals has received guidance from the FDA for its next trial for Next Generation Chemotherapy-Capecitabine (NGC-Cap). The trial will be a Phase 2 safety-efficacy trial in colorectal cancer patients, following FDA's Project Optimus Oncology Initiative. NGC-Cap is designed to decrease side effects while increasing exposure to cancer-killing molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Processa Pharmaceuticals (PCSA)?

The current stock price of Processa Pharmaceuticals (PCSA) is $0.53 as of February 21, 2025.

What is the market cap of Processa Pharmaceuticals (PCSA)?

The market cap of Processa Pharmaceuticals (PCSA) is approximately 2.6M.

What is Processa Pharmaceuticals, Inc.?

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oncology drug products.

When was Processa Pharmaceuticals founded?

Processa Pharmaceuticals was founded in October 2017.

Where is Processa Pharmaceuticals headquartered?

The company is headquartered in Hanover, Maryland.

What is the mission of Processa Pharmaceuticals?

The mission is to develop products that improve the survival and quality of life for patients with high unmet medical needs.

What does NGC stand for?

NGC stands for Next Generation Chemotherapy.

What are the main products in Processa Pharmaceuticals' pipeline?

The main products include NGC-Capecitabine (NGC-Cap), PCS3117 (NGC-Gemcitabine), and PCS11T (NGC-Irinotecan).

What is the unique approach of Processa Pharmaceuticals?

The company uses a 'regulatory science' approach to develop new chemical entities that enhance the properties of FDA-approved cancer drugs.

How can investors get more information about Processa Pharmaceuticals?

Investors can contact Patrick Lin at plin@processapharma.com for more information.

What recent achievements has Processa Pharmaceuticals made?

Recent achievements include advancements in their NGC treatments and ongoing clinical trials.

Does Processa Pharmaceuticals have any partnerships?

Yes, the company engages in strategic partnerships to advance its mission and bring new treatments to market.
Processa Pharmaceuticals Inc

Nasdaq:PCSA

PCSA Rankings

PCSA Stock Data

2.61M
4.34M
8.74%
1.79%
2.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
HANOVER